SINCE the original studies of Barnes, Loutit and Neal (1956) , allogeneic lymphoid cells from either normal or specifically immunized donors have been used in various ways, either alone or in combination with other forms of therapy, to inhibit tumour growth (Fefer, 1973; Santos, 1972) . Usually allogeneic cells have been more effective against leukaemias or ascites tumours than solid tumours (Wigzell, 1] 961; Woodruff, Symes and Stuart, 1963) and any inhibitory effect observed has appeared rather as prolonged survival than complete suppression of tumour growth Ellman et al., 1972) . In some instances, extensive destruction of tumour has occurred but this beneficial effect has been offset by a high mortality from graft-versus-host disease (Woodruff and Symes, 1962) . We now describe experiments in which a non-fatal graft-versus-host reaction frequently produced complete inhibition of growth of a weakly antigenic strain specific transplantable squamous carcinoma which has been maintained in a highly inbred subline of Wistar rats (Baldwin, 1966) . Developing from these studies, additional experiments were designed to determine the immunotherapeutic value of this graft-versus-host effect in preventing recurrence of tumours after resection of small tumours (about 10 mm in diameter); the preliminary results of these experiments are presented. In a previous investigation, this tumour has been shown to be capable ofgrowing in Fl hybrids between this subline and DA (Agouti) rats, but it will not grow in homozygous DA rats (Rumma and Davies, 1974 The effectiveness of the treatment was measured by the number of rats surviving more than 3 months. They are referred to as "cures" in the results.
In Study 1, the results of several experiments of the same kind were pooled and are summarized in Table I . In control rats, all 23 given tumour alone and 31 of 32 given tumour and syngenieic spleen cells died with widespread metastases; in the remaining one animal in the latter group the tumour grew to a diameter of 4 mm and then regressed completely. In those rats injected with spleen cells from the tumour susceptible Wistar parental strain there was a marked reduction of mortality from the tumour, particularly with doses of 25 x 106 and 50 x 106 cells. In some of these the tumour failed to take but in others it grew up to a diameter of 15 mm over a period of 4 weeks before regressing. Histological examination of the tumour inoculation site in these cases showed a small nodule of dense fibrous tissue containing necrotic or degenerate tumour cells. When a dose of lOOx106 and 200X106 Wistar spleen cells was used, mortality was higher but this was mainly due to tumour growth; only one animal given 200 X 106 died from graft-versus-host disease. However, in animals in these groups dying with tumour the survival time was prolonged and, although massive tumours developed at the site of inoculation, there was no evidence of the usual secondary spread to other organs. Tumour regression was also associated with inoculation of spleen cells from the tumour resistant DA parental strain rats with all but the lowest cell dose but, in contrast with the Wistar cells, DA cells produced a high mortality from graft-versus-host disease so that there were few survivors in this group. In 2 rats given 25 x 106 DA cells tumours which grew up to a diameter of 25 mm over 4 weeks regressed, in one completely, while in the other rat the tumour regressed to a diameter of 7 mm, however, only to resume progressive growth, eventually killing the host.
Regression of tumours also occurred on occasions with inoculation of allogeneic Lewis cells at most doses. These cells were less effective than parental Wistar strain cells when considering the number of survivors but they did not induce graft-versus-host disease so that there were more survivors than in the group given DA cells.
The preliminary results of the immunotherapeutic value of a graft-versus-host reaction in preventing the recurrence of tumours in surgically resected animals are summarized in Table II . The most effective regimen was obtained with application of a graft-versus-host reaction on Day 14, followed by surgery on Day 21. In the same regimen, when immunotherapy was delayed for 7 days the number of cures decreased. Immunotherapy alone on Day 14 was unable to cope with established tumours (unpublished observations).
The results show that injection of non-syngeneic spleen cells can in a limited range prevent the growth of a solid transplanted malignant tumour without causing death from graft-versus-host disease (Table I) . Previous studies have shown that lymphoid cells of different inbred strains of rats vary considerably in the type of graft-versus-host reaction that they produce (Elkins, 1970) and in the present study lethal disease occurred consistently more often with parental DA cells than with equivalent doses of Wistar cells of the other parental strain, although this was not paralleled by any significantly greater effectiveness in inhibiting tumour growth. As has been shown previously with a methylcholanthrene induced sarcoma (Medzihradsky, 1969; Medzihradsky, Konikova and Novotna, 1973) , increasing the dose of lymphoid cells beyond a certain level produces less inhibition of tumour growth as well as increased mortality from graftversus-host disease.
Because the lymphoid cells that were most effective in producing tumour inhibition are syngeneic with the tumour, this effect cannot be explained as an allograft rejection reaction. We are probably witnessing an example of the allogeneic effect in which a variety of immunological and inflammatory responses are stimulated by foreign lymphoid cells (Elfenbein, Green and Paul, 1974; Osborne and Katz, 1973) ; this effect has previously been shown to inhibit progress of leukaemia Ellman et al., 1972) . The tumour used in the present study excites a weak host cellular immune response which does not obviously affect growth (Flannery et al., 1973) but injection of BCG can induce host resistance to this tumour (Baldwin and Pimm, 1973) and perhaps the injection of parental or allogeneic lymphoid cells gives a similar augmentation of host anti-tumour immune response. In fact, preliminary results have shown under in vitro conditions that, shortly after the induction of a graftversus-host reaction, spleen cells from tumour bearing Fl hybrids exert a significantly stronger cytotoxic effect upon tumour target cells of the tumour susceptible Wistar parental strain than spleen cells from animals given tumour alone (Rumma, in preparation) . Furthermore, the possibility that the cancerous hosts were being stimulated to cope with metastases when a touch of graft-versushost reaction was used in combination with surgical excision was indicated by the marked increase in cures obtained with this combination of therapies than when surgery alone was used. However, the fact that no significant prolongation of survival of the remaining rats was obtained in the combined therapy would indicate that survival might well have been dependent upon a critical ratio of metastases to immune response status. Nevertheless, the preliminary results strongly suggest that a controlled graft-versus-host reaction might become an effective anti-tumour adjunct in controlling residual tumour remaining after excision of the main mass.
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